HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing

Virchows Archiv

Volumn 457, Issue 3, 2010, Pages 299-307

  Rüschoff, Josef ^a   Dietel, Manfred ^b   Baretton, Gustavo ^c   Arbogast, Susanne ^d   Walch, Axel ^e   Monges, Geneviéve ^f   Chenard, Marie Pierre ^g   Penault Llorca, Frédérique ^h   Nagelmeier, Iris ^a   Schlake, Werner ⁱ   Hofler H ^j   Kreipe, H H ^k  

^a Pathologie Nordhessen U Targos GmbH   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d ROCHE DIAGNOSTICS GMBH   (Germany)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f INSTITUT PAOLI CALMETTES   (France)

^g HÔPITAL DE HAUTEPIERRE   (France)

^h CENTRE JEAN PERRIN   (France)

ⁱ Pathologisches und Gewerbepathologisches Institut   (Germany)

^j UNIVERSITY OF MUNICH   (Germany)

^k HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

Diagnostic test; Gastric carcinoma; HER2; Immunohistochemistry (IHC)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; STOMACH CANCER; GENETICS; OBSERVER VARIATION; PROCEDURES; REPRODUCIBILITY; STANDARDS; STOMACH NEOPLASMS; TISSUE MICROARRAY; VALIDATION STUDY;

HUMANS; IMMUNOHISTOCHEMISTRY; OBSERVER VARIATION; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77956895978     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-010-0952-2     Document Type: Article

References (33)

1. R Simon A Nocito T Hübscher C Bucher J Torhorst P Schraml L Bubendorf MM Mihatsch H Moch K Wilber A Schötzau J Kononen G Sauter 2001 Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer J Natl Cancer Inst 93 1141 1146 1:CAS:528:DC%2BD3MXmtVGqsLc%3D 10.1093/jnci/93.15.1141 11481385
2. A Vincent-Salomon JY Pierga J Couturier CD d'Enghien C Nos B Sigal-Zafrani M Lae P Fréneaux V Diéras JP Thiéry X Sastre-Garau 2007 HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br J Cancer 96 654 659 1:CAS:528: DC%2BD2sXhvV2jtr0%3D 10.1038/sj.bjc.6603584 17262082
3. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 1:CAS:528:DyaL2sXhtVSht7s%3D 10.1126/science.3798106 3798106
4. DJ Slamon W Godolphin LA Jones JA Holt SG Wong DE Keith WJ Levin SG Stuart J Udove A Ullrich, et al. 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707 712 1:STN:280: DyaL1M3kt1Wntg%3D%3D 10.1126/science.2470152 2470152
5. JS Ross JA Fletcher 1998 The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy Oncologist 3 237 252 10388110
6. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 1:CAS:528:DC%2BD3MXisVGktrc%3D 10.1056/NEJM200103153441101 11248153 (Pubitemid 32222155)
7. M Marty F Cognetti D Maraninchi R Snyder L Mauriac M Tubiana-Hulin S Chan D Grimes A Antón A Lluch J Kennedy K O'Byrne P Conte M Green C Ward K Mayne JM Extra 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group J Clin Oncol 23 4265 4274 1:CAS:528: DC%2BD2MXms12gs70%3D 10.1200/JCO.2005.04.173 15911866 (Pubitemid 46207001)
8. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr NE Davidson E Tan-Chiu S Martino S Paik PA Kaufman SM Swain TM Pisansky L Fehrenbacher LA Kutteh VG Vogel DW Visscher G Yothers RB Jenkins AM Brown SR Dakhil EP Mamounas WL Lingle PM Klein JN Ingle N Wolmark 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 1:CAS:528:DC%2BD2MXhtFansr3F 10.1056/NEJMoa052122 16236738 (Pubitemid 41464706)
9. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ; HERA study team 2007 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 29 36 10.1016/S0140-6736(07)60028-2 (Pubitemid 46039831)
10. L Arnould P Arveux J Couturier M Gelly-Marty C Loustalot F Ettore C Sagan M Antoine F Penault-Llorca B Vasseur P Fumoleau BP Coudert 2007 Pathological complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification Clin Cancer Res 13 6404 6409 1:CAS:528: DC%2BD2sXht1CgtbzO 10.1158/1078-0432.CCR-06-3022 17975153 (Pubitemid 350075030)
11. M Hofmann O Stoss D Shi R Büttner M van de Vijver W Kim A Ochiai J Rüschoff T Henkel 2008 Assessment of a HER2 scoring system for gastric cancer: results from a validation study Histopathology 52 797 805 1:STN:280:DC%2BD1czjtFWlsA%3D%3D 10.1111/j.1365-2559.2008.03028.x 18422971 (Pubitemid 351724903)
12. DI Park JW Yun JH Park SJ Oh HJ Kim YK Cho CI Sohn WK Jeon BI Kim CH Yoo BH Son EY Cho SW Chae EJ Kim JH Sohn SH Ryu AR Sepulveda 2006 HER-2/neu amplification is an independent prognostic factor in gastric cancer Dig Dis Sci 51 1371 1379 1:CAS:528:DC%2BD28Xosleqs7Y%3D 10.1007/s10620-005-9057-1 16868827 (Pubitemid 44315804)
13. T Yano T Doi A Ohtsu N Boku K Hashizume M Nakanishi A Ochiai 2006 Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer Oncol Rep 15 65 71 16328035
14. XL Zhang YS Yang DP Xu JH Qu MZ Guo Y Gong J Huang 2009 Comparative study on overexpression of her2/neu and her3 in gastric cancer World J Surg 33 2112 2118 10.1007/s00268-009-0142-z 19636613
15. S Uchino H Tsuda K Maruyama T Kinoshita M Sasako T Saito M Kobayashi S Hirohashi 1993 Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients Cancer 72 3179 3184 1:STN:280:DyaK2c%2FmtFOntA%3D%3D 10.1002/1097-0142(19931201)72:11<3179::AID- CNCR2820721108>3.0.CO;2-# 7902202 (Pubitemid 23356757)
16. M Nakajima H Sawada Y Yamada A Watanabe M Tatsumi J Yamashita M Matsuda T Sakaguchi T Hirao H Nakano 1999 The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas Cancer 85 1894 1902 1:CAS:528:DyaK1MXjtVCqsro%3D 10223227
17. H Allgayer R Babic KU Gruetzner A Tarabichi FW Schildberg MM Heiss 2000 c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems J Clin Oncol 18 2201 2209 1:STN:280:DC%2BD3c3ptFajtw%3D%3D 10829039
18. I García F Vizoso A Martín L Sanz O Abdel-Lah P Raigoso JL García-Muñiz 2003 Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer Ann Surg Oncol 10 234 241 10.1245/ASO.2003.05.010 12679307 (Pubitemid 40486955)
19. M Tanner M Hollmén TT Junttila AI Kapanen S Tommola Y Soini JL García-Muñiz 2005 Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab Ann Oncol 16 273 278 1:STN:280:DC%2BD2M%2FjvFyhsg%3D%3D 10.1093/annonc/mdi064 15668283 (Pubitemid 40309309)
20. Y Matsui M Inomata M Tojigamori K Sonoda N Shiraishi S Kitano 2005 Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model Int J Oncol 27 681 685 1:CAS:528:DC%2BD2MXpvVWmtLk%3D 16077916
21. K Fujimoto-Ouchi F Sekiguchi H Yasuno Y Moriya K Mori Y Tanaka 2007 Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models Cancer Chemother Pharmacol 59 795 805 1:CAS:528:DC%2BD2sXjt1WmtLs%3D 10.1007/s00280-006-0337-z 17031648 (Pubitemid 46440603)
22. Van Cutsem E, Kang Y, Chung H, Sawaki A, Lordick F, Hill J, Lehle M, Feyereislova A, Bang Y (2009) Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27:18 s (suppl; abstr LBA4509)
23. Bang Y, Van Cutsem C, Feyereislova A, Chung H, Shen L, Sawaki S, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang Y-K (2010) Phase III, randomised clinical trial to compare trastuzumab in combination with chemotherapy versus chemotherapy alone for the treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer. Lancet, submitted
24. EMEA, European Medicines Agency (2009): Opinion www.emea.europa.eu/pdfs/ human/opinion/Herceptin-82246709en.pdf
25. Bang Y, H. Chung H, Xu J, Lordick F, Sawaki A, Al-Sakaff N, Lipatov O, See C, Rueschoff J, Van Cutsem E (2009) Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 27:15s (suppl; abstr 4556)
26. M Dietel IO Ellis H Höfler H Kreipe H Moch A Dankof K Kölble G Kristiansen 2007 Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists Virchows Arch 451 19 25 1:CAS:528:DC%2BD2sXpsVOiurk%3D 10.1007/s00428-007-0424-5 17562074
27. JD Barros-Silva D Leitão L Afonso J Vieira M Dinis-Ribeiro M Fragoso MJ Bento L Santos P Ferreira S Rêgo C Brandão F Carneiro C Lopes F Schmitt MR Teixeira 2009 Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients Br J Cancer 100 487 493 1:CAS:528:DC%2BD1MXhsFeksbc%3D 10.1038/sj.bjc.6604885 19156142
28. C Tapia K Glatz H Novotny A Lugli M Horcic CA Seemayer L Tornillo L Terracciano H Spichtin M Mirlacher R Simon G Sauter 2007 Close association between HER-2 amplification and overexpression in human tumors of non-breast origin Mod Pathol 20 192 198 1:CAS:528:DC%2BD2sXivVSlsb0%3D 10.1038/modpathol. 3800729 17361205 (Pubitemid 46422173)
29. AH Marx L Tharun J Muth AM Dancau R Simon E Yekebas JT Kaifi M Mirlacher TH Brümmendorf C Bokemeyer JR Izbicki G Sauter 2009 HER-2 amplification is highly homogenous in gastric cancer Hum Pathol 40 769 777 1:CAS:528: DC%2BD1MXmtFektb8%3D 10.1016/j.humpath.2008.11.014 19269014
30. M Dowsett M Procter W McCaskill-Stevens E de Azambuja U Dafni J Rueschoff B Jordan S Dolci M Abramovitz O Stoss G Viale RD Gelber M Piccart-Gebhart B Leyland-Jones 2009 Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA trial J Clin Oncol 27 2962 2969 1:CAS:528:DC%2BD1MXoslyis70%3D 10.1200/JCO.2008.19.7939 19364966
31. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Allred RJ Cote M Dowsett PL Fitzgibbons WM Hanna A Langer LM McShane S Paik MD Pegram EA Perez MF Press A Rhodes C Sturgeon SE Taube R Tubbs GH Vance M van de Vijver TM Wheeler DF Hayes 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118 145 1:CAS:528:DC%2BD2sXht1ejs7Y%3D 10.1200/JCO.2006.09.2775 17159189 (Pubitemid 350003059)
32. J Rüschoff I Nagelmeier G Baretton M Dietel H Höfler HU Schildhaus R Büttner W Schlake O Stoss HH Kreipe 2010 HER2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe 31 208 217 10.1007/s00292-010-1278-1 20443098 [German]
33. AJ Conger 1980 Integration and generalization of Kappa for multiple raters Psychol Bull 88 322 328 10.1037/0033-2909.88.2.322